Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | HTR6 | P50406 | 7/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31521684 | 1.00 | KDR (0.68) | KDRHTR6ADRB1NCF1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9128302 | 0.98 | KDR (0.66) | KDRHTR6ADRB1NCF1CYP1A2 | |
| SCHEMBL31521642 | 0.87 | KDR (0.53) | KDRCYP1A2CYP2D6TSHRHSD17B10 | |
| SCHEMBL29018544 | 0.86 | ALDH1A1 (0.51) | KDRNCF1CYP1A2HSD17B10CYP2C19 | |
| SCHEMBL31521650 | 0.82 | TSHR (0.49) | KDRCYP1A2CYP2D6TSHRHSD17B10 | |
| SCHEMBL31521682 | 0.82 | CYP11B1 (0.54) | KDRCYP1A2CYP2D6TSHRHSD17B10 | |
| SCHEMBL1442519 | 0.81 | HTR6 (0.60) | KDRHTR6ADRB1NCF1CYP1A2 | |
| SCHEMBL30059045 | 0.81 | KDR (0.80) | KDRHTR6ADRB1HTR1AHTR7 | |
| SCHEMBL30059061 | 0.81 | KDR (0.59) | KDRHTR6ADRB1NCF1CYP1A2 | |
| SCHEMBL31521668 | 0.80 | ALDH1A1 (0.49) | KDRCYP1A2CYP2D6TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732146-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732146-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1389110-B1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | AVANIR PHARMACEUTICALS (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7514225-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514225-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7435737-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTIALS (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435737-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTIALS (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070232613-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-10-04 | — | — | US | disclosed |
| US-20070232613-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-10-04 | — | — | US | disclosed |
| US-7202248-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202248-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-04-10 | — | — | US | disclosed |
| US-7192955-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192955-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192961-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192961-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-01-25 | — | — | US | disclosed |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-01-25 | — | — | US | disclosed |
| US-7157469-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157469-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232613-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | KDR 1186/4885HTR6 3900/4885ADRB1 1547/4885 |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | KDR 1186/4885HTR6 3900/4885ADRB1 1547/4885 |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | KDR 768/4885HTR6 3913/4885ADRB1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.